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Objectives. This report characterizes the paradoxical sinus
deceleration occasionally observed during dobutamine stress test-
ing and determines its relation to myocardial ischemia.
Background. Dobutamine stress echocardiography is widely
accepted as a noninvasive tool for evaluating coronary artery
disease. With infusion of dobutamine, there is typically a dose-
dependent increase in heart rate. However, in some patients, a
paradoxical decrease in heart rate has been observed during high
dose dobutamine infusion.
Methods. In 181 consecutive patients undergoing both dobut-
amine stress echocardiography and coronary angiography, elec-
trocardiographic (ECG) data collected during dobutamine infu-
sion were reviewed to identify patients with a decrease in heart
rate. The clinical, stress echocardiographic, hemodynamic and
angiographic correlates of patients with a decrease in heart rate
were reviewed.
Results. A decrease in heart rate ranging from 7 to 64 beats/min
occurred during high dose dobutamine infusion in 14 patients
(8%, 95% confidence interval [CI] 6% to 10%), including 3 in
whom a junctional rhythm developed. The decrease was sudden in
five patients (36%, 95% CI 13% to 65%) and gradual in nine (64%,
95% CI 35% to 87%). A decrease in blood pressure (12 patients
[86%], 95% CI 57% to 98%) with simultaneous chest pain (7
patients [50%], 95% CI 23% to 77%) and nausea (5 patients
[36%], 95% CI 13% to 65%) was common. Significant coronary
artery disease (>250% diameter stenosis) was present in 8 (57%) of
14 patients (95% CI 29% to 82%). Two patients (14%, 95% CI 2%
to 43%) had no clinical, ECG or echocardiographic evidence of
ischemia and no significant coronary artery disease by angiogra-
phy. There was no increased incidence of right coronary artery
stenosis in patients with paradoxical sinus deceleration.
Conclusions. Paradoxical sinus deceleration occurs in 8% of
patients during dobutamine stress testing. Although most often
observed in patients with coronary artery disease, it can occur in
the absence of ischemia and coronary artery disease, and in some
patients may be due to a vasodepressor reflex.
(J Am Coll Cardiol 1997;29:994–9)
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Dobutamine stress echocardiography is widely accepted as a
noninvasive tool for evaluating coronary artery disease. The
synthetic catecholamine dobutamine has predominant beta1-
but also beta2- and alpha-receptor agonistic activity (1,2).
During infusion of low doses of dobutamine, the predominant
hemodynamic effect is an increase in myocardial contractility;
with higher doses, there is a dose-dependent increase in heart
rate (3,4). The induction of myocardial ischemia during dobut-
amine infusion is presumably dependent on achieving a satis-
factory chronotropic response. During dobutamine stress
echocardiography, an attempt is made to reach a heart rate of
at least 85% of the maximal rate predicted for age (5).
In some patients we have observed a paradoxical decrease
in heart rate during high dose dobutamine infusion. This
cardioinhibitory response may be a manifestation of the
Bezold-Jarisch reflex. Induction of this reflex increases para-
sympathetic activity and inhibits sympathetic activity, resulting
in bradycardia, which may be accompanied by vasodilation,
nausea and hypotension. The Bezold-Jarisch reflex has been
stimulated in the settings of myocardial infarction (preferen-
tially inferoposterior location), coronary angiography and va-
sovagal syncope. Additionally, some drugs, including isopro-
terenol, can sensitize or desensitize cardiac sensory receptors
that have vagal afferent pathways (6–8). The purpose of the
present study was to characterize the decrease in heart rate
that occurs during dobutamine stress echocardiography and to
determine its relation to inferoposterior ischemia.
Methods
Patients. Data from all patients in our database who
underwent both dobutamine stress echocardiography and cor-
onary angiography within 6 months (mean [6SD] 24 6 49
days) at our institution from January 1990 to June 1994 were
reviewed. Exclusion criteria were atrial fibrillation and previ-
ous or intervening revascularization (coronary artery bypass
graft surgery or coronary angioplasty). Of the 181 patients who
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fulfilled the inclusion criteria, 112 were men and 69 were
women (mean age 68 6 10 years, range 36 to 88). The
pertinent medical history, demographics, hemodynamic vari-
ables, electrocardiographic (ECG) data and echocardiographic
findings were recorded for all patients at the time of stress
echocardiography.
Dobutamine stress echocardiography. Dobutamine stress
echocardiography was performed according to a previously
described protocol (9) in patients abstaining from oral intake
for $3 h. The beginning infusion rate of dobutamine was
5 mg/kg body weight per min, and the dose was increased every
3 min to 10, 20, 30, 40 and, if needed, 50 mg/kg per min. From
January 1992 onward, atropine (in divided doses of 0.25 to
0.5 mg) was administered when the heart rate response to
dobutamine infusion of 40 mg/kg per min was inadequate, as
judged by the clinician performing the study. Heart rate was
recorded every minute during dobutamine infusion and for at
least 10 min of recovery. Blood pressure was measured every
3 min; if there was a decrease in systolic blood pressure,
measurements were obtained every minute. If systolic blood
pressure decreased to #90 mm Hg, the patient’s legs were
tilted upward to counteract the hypotension. Ejection fraction
was calculated according to the modified method of Quinones
et al. (10). Wall motion was assessed by consensus of two
experienced stress echocardiographers who were unaware of
the findings of coronary angiography. Regional wall motion
analysis was performed semiquantitatively with a 16-segment
model of the left ventricle (11). Each segment was assigned a
score based on its wall motion and thickening, and the wall
motion score index was calculated as the sum of the scores
divided by the number of visualized segments. The segments
were classified into three coronary artery distributions. The
anterior region was the territory of the left anterior descending
coronary artery, and the posterior distribution included the left
circumflex and right coronary artery territories.
Paradoxical sinus deceleration. A decrease in heart rate was
defined as a decrease .5 beats/min lasting at least 3 min during
the continuous incremental dobutamine infusion.
Coronary angiography. Coronary angiograms were ana-
lyzed by two experienced angiographers who had no knowl-
edge of the clinical data and the results of dobutamine stress
echocardiography. They visually estimated the coronary artery
narrowing and expressed it as percent stenosis of the lumen
diameter. Significant coronary stenosis was defined as $50%
narrowing of the lumen diameter of the major epicardial
coronary arteries or any of their major branches.
Statistical analysis. Results are presented as mean value 6
SD or frequency expressed as a percentage with 95% confi-
dence intervals. Two-sample t tests or Pearson chi-square tests
for 2 3 2 tables were used to assess the association of each
variable separately with the presence of a decrease in heart
rate.
Results
Description of sinus deceleration. Sinus deceleration oc-
curred in 14 patients (8%, 95% confidence interval [CI] 6% to
10%), including 3 in whom a junctional rhythm developed
(Tables 1 and 2). These 14 patients had a decrease in heart rate
from 7 to 64 beats/min. The decrease occurred at dobutamine
doses ranging from 20 to 40 mg/kg per minute; in no patient did
Abbreviations and Acronyms
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
Table 1. Summary of Heart Rate and Systolic Blood Pressure Response in 14 Patients With Paradoxical Sinus Deceleration
Pt No.
Dobutamine
(mg/kg per min)*
Rest HR
(beats/min)
Rest SBP
(mm Hg)
Max HR with
Dobutamine
(beats/min)
Subsequent HR
Decrease
(beats/min)†
HR After
Decrease
(beats/min)‡
SBP at Peak
Dobutamine
(mm Hg)
Change in SBP
(mm Hg)§
1 40 79 170 119 211 108 128 229
2 30 93 181 129 29 120 159 249
3 40 72 121 114 222 92 155 225
4 40 56 151 102 237 65 (junct) 115 13
5 40 74 132 120 27 113 91 23
6 40 87 134 110 258 52 (junct) 102 15
7 40 74 157 110 225 85 120 233
8 40 95 157 128 29 119 158 240
9 40 82 129 122 222 100 128 246
10 40 63 125 115 27 108 109 229
11 40 86 160 124 264 60 (junct) 108 230
12 40 80 148 120 242 78 169 217
13 20 78 144 116 212 104 115 225
14 40 65 142 88 224 64 115 26
*Dose of dobutamine when heart rate (HR) decreased. †Decrease in heart rate from peak rate during dobutamine infusion. ‡Minimal heart rate during paradoxical
decrease. §Extent of decrease in blood pressure is change in systolic blood pressure (SBP [mm Hg]) from previous measurement concomitant with decrease in heart
rate. junct 5 junctional rhythm; Max 5 maximal; Pt 5 patient.
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heart rate decrease after administration of atropine. The
decrease was sudden (the maximal decrease occurred within
#1 min) in five patients (Patients 2, 5, 7, 10 and 12) and
occurred more gradually in the other nine. The minimal heart
rate was ,60 beats/min in only one patient (Patient 6) (Fig. 1)
and was ,80 beats/min in five. In nine patients (64%, 95% CI
35% to 87%), the decrease in heart rate was accompanied by a
decrease in systolic blood pressure .20 mm Hg. In three
of these patients, systolic blood pressure decreased to
,90 mm Hg. The decrease in heart rate was interrupted by
stopping the dobutamine infusion (in nine patients), increasing
the rate of infusion (in one patient) or by injecting atropine (in
four patients). Although the dose of dobutamine was increased
in six patients, this dose was beneficial in increasing the heart
rate in only one. In the four patients (Patients 3, 8, 11 and 14)
who received atropine (0.5 to 1.0 mg), heart rate increased by
42 to 82 beats/min (mean 59 6 20 beats/min) (Fig. 2).
Clinical variables in patients with and without sinus decel-
eration (Table 3). Only 1 of the 14 patients with a decrease in
heart rate (7%, 95% CI 0% to 14%) was taking a beta-
adrenergic blocker, as opposed to 44 of 167 patients (26%,
95% CI 23% to 29%) with no decrease in heart rate (p 5 0.11).
Stress echocardiographic correlates. Heart rate, rate-
pressure product, symptoms, ECG data and echocardiographic
findings for the two groups are summarized in Table 4. Mean
ejection fractions in the two groups were similar. In the
patients with a decrease in heart rate, ejection fraction at rest
ranged from 20% to 70%. The increase in heart rate achieved
during dobutamine infusion and the rate-pressure product at
peak stress were significantly lower in patients with a decrease
in heart rate (p 5 0.005 and p 5 0.006, respectively). Chest
pain occurred significantly more often in the 14 patients with a
decrease in heart rate (50%, 95% CI 23% to 77% vs. 22%,
95% CI 19% to 25%, p 5 0.02). Nausea was also more
common in these 14 patients (36%, 95% CI 13% to 65% vs.
4%, 95% CI 2% to 6%, p 5 0.0008). Wall motion score index
at peak stress was similar in both groups (p 5 0.48).
Angiographic correlates. Significant coronary artery dis-
ease was present in 154 (85%) of 181 patients (95% CI 82% to
88%) (one-vessel disease in 33, two-vessel disease in 52,
three-vessel disease in 70). Twenty-seven patients (15%, 95%
CI 12% to 18%) had no significant coronary artery disease.
Heart rate decreased in 8 (5%) of 154 patients (95% CI 2% to
9%) with and 6 (22%) of 27 patients (95% CI 9% to 42%)
without coronary artery disease. Among patients with a de-
crease in heart rate during dobutamine stress echocardiogra-
phy, significant coronary artery disease was less common (57%,
95% CI 29% to 82% vs. 87%, 95% CI 84% to 90%, p 5 0.002)
(Tables 1 to 3). Stenosis of the left anterior descending and left
circumflex coronary arteries was significantly less frequent
(p 5 0.04 and p 5 0.02, respectively) in patients with than
without a decrease in heart rate; however, the incidence of
right coronary artery stenosis was similar in both groups (p 5
0.21). In one patient (Patient 7) with 50% diameter stenosis of
the middle right coronary artery, the dobutamine stress test
result was clinically, electrocardiographically and echocardio-
graphically negative for ischemia. In this patient, the test was
terminated because of a decrease in blood pressure that
accompanied the decrease in heart rate. Target heart rate was
not achieved, and the rate-pressure product at peak stress was
Table 2. Summary of Symptoms, Wall Motion Abnormalities and Electrocardiographic and
Angiographic Findings in 14 Patients With Paradoxical Sinus Deceleration
Pt No./Gender Age (yr) Symptoms
New or
Worsening LV
Regional Wall
Motion
Abnormalities
CAD ECGAnt Post
1/F 79 CP, D 1 1 0 Nondiag
2/F 64 CP, D 2 2 0 Pos
3/M 66 CP 2 2 0 Neg
4/M 68 N 2 2 0 Nondiag
5/M 56 D 1 1 0 Neg
6/F 65 N, HA 2 2 0 Neg
7/M 67 N 2 2 RCA Neg
8/F 62 N 1 1 RCA Pos
9/F 67 None 1 2 LAD Nondiag
10/M 73 CP, D 1 1 LAD, RCA Pos
11/M 61 N 1 1 3 VD Neg
12/M 46 CP, D 1 1 3 VD Neg
13/M 69 CP, D 1 1 3 VD Pos
14/F 67 CP 1 2 3 VD Nondiag
Ant 5 anterior; CAD 5 coronary artery disease; CP 5 chest pain; D 5 dyspnea; ECG 5 electrocardiography; F 5
female; HA 5 headache; LAD 5 left anterior descending coronary artery; LV 5 left ventricular; M 5 male; N 5 nausea;
Neg 5 negative; Nondiag 5 nondiagnostic; Pos 5 positive for ischemia; Post 5 posterior; RCA 5 right coronary artery;
VD 5 vessel disease; 1 5 yes; 2 5 no.
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only 7,395 beats/min 3 mm Hg. Among patients with a heart
rate decrease, three of six patients without significant coronary
artery disease (Patients 1, 4 and 5) had 40% diameter stenosis
in either the right coronary artery or the left anterior descend-
ing coronary artery. Two of these patients (Patients 1 and 5)
had rest wall motion abnormalities and new or worsening wall
motion abnormalities.
Discussion
The present study describes the paradoxical sinus deceler-
ation that may occur during dobutamine stress echocardiogra-
phy. This decrease in heart rate can be sudden or gradual.
Sinus deceleration was observed in patients with and without
coronary artery disease and inducible myocardial ischemia and
was not predictive of the site or the extent of coronary artery
disease. Sinus deceleration was frequently accompanied by a
decrease in systolic blood pressure, which occurred in 8 (57%)
of the 14 patients. In addition, nausea and chest pain were
significantly more common in patients with a decrease in heart
rate.
Comparison with previous studies. Sinus deceleration dur-
ing dobutamine stress echocardiography has not been exten-
sively described. The first documentation of a decrease in heart
rate during dobutamine infusion was found during dobutamine
therapy in horses; sinus bradycardia developed in 17% (12).
Mertes et al. (13), reporting on adverse effects during dobut-
amine stress echocardiography in 1,118 patients, stated that
bradycardia was the reason for termination of the test in only
2 patients (0.2%), and junctional rhythm was present in 2.5%
of patients; it was not reported how often a decrease in heart
rate occurred with or without causing bradycardia. Both Mar-
covitz et al. (14) and Rosamond et al. (15), analyzing the
occurrence of hypotension during dobutamine stress echocar-
diography, specifically mentioned that a decrease in heart rate
Figure 1. A, Findings in a 65-year old woman (Patient 6) undergoing
dobutamine stress echocardiography for evaluation of atypical chest
pain. Headache developed during dobutamine infusion at dosage of
20 mg/kg per min. At 40 mg/kg per min, her heart rate suddenly
decreased to 52 beats/min (bpm). Within 2 min of stopping the
dobutamine infusion, her heart rate had increased to 92 beats/min.
Results of stress echocardiography were negative for ischemia. Coro-
nary angiography showed no significant disease. B, Corresponding
ECG.
Figure 2. Findings in a 61-year old man (Patient 11) who was
asymptomatic throughout dobutamine infusion (A). However, at a
dosage of 40 mg/kg per min, his heart rate suddenly decreased from 124
to 60 beats/min (bpm). Electrocardiography (B) showed slowing sinus
rhythm with intermittent junctional escape rhythm. Atropine, 0.5 mg,
was injected while dobutamine infusion was continued, and heart rate
increased to 142 beats/minute. Results of stress echocardiography were
positive for ischemia in both anterior and posterior circulations.
Coronary angiography showed three-vessel disease with 60% stenosis
of the mid-left anterior descending coronary artery, 50% of the
proximal circumflex coronary artery and 70% of the proximal right
coronary artery.
997JACC Vol. 29, No. 5 ATTENHOFER ET AL.
April 1997:994–9 SINUS DECELERATION DURING DOBUTAMINE STRESS
was not associated with the decrease in blood pressure and that
the mean heart rate was actually higher in patients with a
decrease in blood pressure. Analyzing hypotension during
dobutamine stress echocardiography, Mazeika et al. (16),
however, found a concomitant decrease in heart rate in six of
seven patients; but they did not report whether heart rate
decreased without a decrease in blood pressure. Hopfenspirger
et al. (17) recently reported sinus deceleration of 4 to 38
beats/min during dobutamine–perfusion scintigraphy in 10
(17%) of 58 patients. They found scintigraphic evidence of
inferior wall ischemia in all these patients. Coronary angio-
graphic correlation was not available. This finding is in contrast
to our experience, in which 6 (43%) of 14 patients did not have
significant coronary artery disease. Stenosis of 40% of the
lumen diameter was present in three of these patients, two of
whom had worsening of wall motion abnormalities with stress.
It is conceivable that the angiographic severity of stenosis in
these three patients was underestimated or that there was
coexistent coronary spasm. However, three patients with par-
adoxical sinus deceleration had angiographically normal coro-
nary arteries. Thus, inappropriate sinus deceleration during
dobutamine infusion cannot be equated with coronary artery
disease.
Mechanism of sinus deceleration. The triad of bradycar-
dia, hypotension and nausea that we observed in some patients
receiving high dose dobutamine could have resulted from
stimulation of large-vessel baroreceptors by increased systolic
pressure, flow or pulse pressure during the dobutamine infu-
sion (18). However, in no patient was the sinus deceleration
preceded by a marked increase in blood pressure. A more
probable mechanism is activation of the Bezold-Jarisch reflex.
This reflex originates in cardiac sensory receptors with nonmy-
elinated vagal afferent pathways (6). The inferoposterior wall
of the left ventricle is the principal location of these sensory
receptors, which can be stimulated by stretch, chemical sub-
stances or drugs; this stimulation results in an increase in
parasympathetic activity and an inhibition of sympathetic
activity. These effects promote reflex bradycardia, vasodilation
and hypotension. In a recent animal study (8) on the vasode-
pressor reaction in the rat, in which cardiac volume was
reduced by vena cava occlusion, a vasodepressor reaction
accompanied by paradoxical bradycardia was induced by infu-
sion of isoproterenol and dobutamine. Induction of a vasode-
pressor response in humans occurs with the administration of
isoproterenol during passive upright tilting in persons with a
propensity for syncope. A vasodepressor reaction can occur in
any setting with reduced intracardiac volume (as is present
during dobutamine stress echocardiography) in combination
with beta1-adrenergic stimulation (dobutamine or isoprotere-
nol). Our patients fasted for 3 h before the dobutamine
infusion; mild hypovolemia may thus have facilitated the
occurrence of this vasodepressor response.
The chronotropic effect of dobutamine may counteract
most of the bradycardia it would otherwise induce by sensitiz-
ing the cardiac baroreceptors; thus, in many patients, there
may be a balance between the positive chronotropic effects of
dobutamine and the negatively chronotropic Bezold-Jarisch
reflex, attenuating a desirable “normal” increase in heart rate.
However, the induction of myocardial ischemia during dobut-
amine stress echocardiography is presumably dependent on
increased heart rate. The paradoxical decrease in heart rate
during dobutamine stress echocardiography could potentially
Table 4. Symptoms and Heart Rate, Electrocardiographic and
Echocardiographic Variables During Dobutamine Stress
Echocardiography in Patients With and Without a Decrease in
Heart Rate
HR Decrease
(n 5 14)
No HR
Decrease
(n 5 167)
p
Value*
Chest pain 7 (50) 36 (22) 0.02
Nausea 5 (36) 7 (4) 0.0008
Rest HR (beats/min) 77 6 11 71 6 12 0.06
Peak HR (beats/min) 113 6 29 122 6 19 0.14
D HR (beats/min) 35 6 23 51 6 20 0.005
D BP (mm Hg) 242 6 233 216 6 226 0.0005
Rest RPP 11,409 6 2,597 10,171 6 2,315 0.06
Peak RPP 12,673 6 5,668 16,228 6 4,471 0.006
ECG positive for ischemia 4 (29) 46 (28) 0.46
Rest LVEF (%) 55 6 13 50 6 13 0.19
Peak LVEF (%) 60 6 17 56 6 16 0.40
Rest WMSI 1.3 6 0.4 1.4 6 0.5 0.23
Peak WMSI 1.6 6 0.4 1.7 6 0.5 0.48
New regional WMAs 9 (64) 122 (73) 0.56
*Statistically significant at p , 0.05. Data presented are number (%) of
patients or mean value 6 SD. ECG 5 electrocardiogram; LVEF 5 left
ventricular ejection fraction; RPP 5 rate–pressure product (heart rate 3 systolic
blood pressure); WMAs 5 wall motion abnormalities; WMSI 5 wall motion
score index; D BP 5 change in blood pressure from maximal blood pressure
recorded; D HR 5 increase in heart rate from rest to peak stress preceding
decrease in heart rate (if present).
Table 3. Clinical Variables and Medication in Patients Undergoing
Dobutamine Stress Echocardiography, According to Heart
Rate Response
HR Decrease
(n 5 14)
No HR Decrease
(n 5 167) p Value*
Age (yr) 65 6 8 68 6 10 0.22
Men/women 8/6 104/63 0.70
Hypertension 8 (57) 106 (63) 0.64
Smoking 9 (64) 120 (72) 0.55
Hyperlipidemia 7 (50) 89 (53) 0.81
Previous MI 4 (29) 63 (38) 0.50
CAD 8 (57) 146 (87) 0.002
Diabetes 4 (29) 39 (23) 0.66
Weight (kg) 78 6 16 77 6 15 0.80
BSA (m2) 1.86 6 0.2 1.86 6 0.2 0.99
Medication
Beta-blockers 1 (7) 44 (27) 0.11
Calcium blockers† 7 (50) 69 (42) 0.54
Digoxin 0 (0) 21 (13) 0.16
*Statistically significant at p , 0.05. †Calcium channel antagonists. Data
presented are mean value 6 SD, ratio or number (%) of patients. BSA 5 body
surface area; CAD 5 coronary artery disease by coronary angiography; MI 5
myocardial infarction.
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result in the underdetection of coronary artery disease. Atro-
pine injection at peak dobutamine infusion is used in patients
who do not achieve 85% of the predicted maximal heart rate
during dobutamine stress echocardiography (5). We have
observed that atropine is also effective in augmenting heart
rate in patients with a paradoxical bradycardia. Therefore, in
the presence of sinus deceleration and in the absence of
echocardiographically detectable ischemia, atropine injection
should be considered, even if the peak dose of dobutamine has
not been given.
Limitations of the study. The present study describes a
select group of patients who underwent dobutamine stress
echocardiography and coronary arteriography. Thus, there is a
referral bias, and the incidence of a decrease in heart rate in
the general population referred for dobutamine stress echo-
cardiography is unknown. However, we specifically chose only
all consecutive patients who underwent coronary angiography
to correlate the effect of coronary anatomy with the chrono-
tropic response.
Conclusions. The present study demonstrates that despite
continuous high dose dobutamine stress infusion, paradoxical
sinus deceleration may occur and is frequently accompanied by
nausea and a decrease in systolic blood pressure. This phe-
nomenon is probably mediated by the Bezold-Jarisch reflex.
Although paradoxical sinus deceleration most often occurs in
the presence of coronary artery disease, it may occur in the
absence of inducible myocardial ischemia or angiographic
coronary artery disease. This reaction can offset the positive
chronotropic effects of dobutamine and can effectively be
reversed with atropine.
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